The new opportunities of treatment of non-alcoholic steatohepatitis
Journal Title: Сучасна гастроентерологія - Year 2018, Vol 0, Issue 1
Abstract
Objective — to evaluate the efficacy and safety of the dietary supplement Schisandrin®, 250 mg tablets (manufacturer Pharmacom Ltd.) in patients with non-alcoholic steatohepatitis. Materials and methods. The investigation involved 40 patients (18 (45 %) men and 22 (55 %) women) with non-alcoholic steatohepatitis (NASH), aged 25 to 65 years old (the mean age 43.6 ± 11.3 years). The control group consisted of 10 healthy subjects. Clinical examinations included assessment of data of anthropometric measuring, blood pressure, determination of serum levels of C-reactive protein (CRP) and TNF-alpha in serum, degree of liver steatosis. The treatment was performed with the drug Schisandrin® for 12 weeks in different dosage regimens: I group — 20 patients receiving the drug Schisandrin® 1 tablet 3 times a day; II group — 20 patients who received the drug Schisandrin® for 2 tablets 3 times a day. Results. In the course of treatment, there was a significant dynamics of the main clinical manifestations, i.e. symptoms’ removal or relief, which more rapidly and substantially reduced in patients of group II, as well as decreased activity of the inflammatory process in the liver tissue. The intake of Schisandrin® significantly reduced the increased ALT and AST activity and level of cholestasis markers in patients with NASH, this effect was dose-dependent, too. By the end of third months of therapy, a decrease in the level of high-sensitivity CRP and serum TNF-α levels in the examined patients was achieved, more substantial changes were observed in patients of group II. The improvement of ultrasound characteristics has been revealed, including tendency towards normalization of the acoustic density and liver size due reduction of steatosis degree. Conclusions. It has been demonstrated that Schisandrin® had a positive effects on the NASH course, with a higher efficacy and dose-dependent effects in the treatment regimen of 2 tablets 3 times a day for 3 months. This dose proved to be highly safe and well tolerated. Schisandrin® can serve as an alternative to the treatment of patients with non-alcoholic fatty liver disease at the NASH stage, not only in the stage of activation of the inflammatory process in the liver tissue, but also at the stage of supportive therapy in order to prevent the disease progression.
Authors and Affiliations
G. D. Fadieienko, O. V. Kolesnikova, T. A. Solomenseva
Keywords
Related Articles
- EP ID EP276249
- DOI -
- Views 132
- Downloads 0
The gastroenterological manifestations of methotrexate effects in pediatric patients with the juvenile idiopathic arthritis
The paper elucidates the most prevalent gastroenterological manifestations of methotrexate effects in the treatment of juvenile idiopathic arthritis (JIA) in pediatric patients. Some considerable changes took place in th...
Scope of application of the ursodeoxycholic acid at gastroenterological pathology
The article presents modern concepts on the using of ursodeoxycholic acid in the clinical practice of internist. The presented review is focused on the effects of ursodeoxycholic acid, the current spectrum of it’s applic...
Functional intestinal symptoms in patients with inflammatory bowel disease: recommendations of the American Gastroenterological Association (2019)
The paper presents overview of the latest recommendations of the American Gastroenterological Association on the management of patients with functional intestinal symptoms (FIS). It was noted that the prevalence of irrit...
The dynamics of results of the esophageal 24-hour multichannel intraluminal impedance-pH monitoring in patients with stable angina and gastroesophageal reflux disease against the background of the basic treatment correction
Due to the mutual aggravating effects in the comorbidity of the stable angina of effort (SAE) and gastroesophageal reflux disease (GERD), the necessity arises for the correction of basic therapy of each of these patholog...
Possibilities of correction of indicators of the humoral and cellular immunity by hepatoprotective ademetionine in the sportsmen of high professional qualification after the competitive period
Objective — to assess the efficacy of the hepatoprotector ademetionine for the correction of immune disorders in athletes of high professional qualification in the post-competitive period. Materials and methods. Examina...